Sumitomo Mitsui Trust Group Inc. Decreases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sumitomo Mitsui Trust Group Inc. decreased its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 9.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,065,050 shares of the biotechnology company’s stock after selling 210,665 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 7.62% of Arcturus Therapeutics worth $35,044,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. ARK Investment Management LLC raised its position in Arcturus Therapeutics by 6.9% in the 3rd quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock worth $48,765,000 after buying an additional 136,074 shares during the last quarter. Geode Capital Management LLC raised its position in Arcturus Therapeutics by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock worth $12,810,000 after buying an additional 5,789 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Arcturus Therapeutics by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock worth $4,587,000 after buying an additional 3,224 shares during the last quarter. Royce & Associates LP raised its position in Arcturus Therapeutics by 18.3% in the 3rd quarter. Royce & Associates LP now owns 155,803 shares of the biotechnology company’s stock worth $3,616,000 after buying an additional 24,085 shares during the last quarter. Finally, Empire Life Investments Inc. purchased a new position in Arcturus Therapeutics in the 3rd quarter worth about $3,498,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ARCT shares. HC Wainwright reissued a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research report on Monday, January 13th. BTIG Research assumed coverage on shares of Arcturus Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $41.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $65.00.

Arcturus Therapeutics Stock Down 0.2 %

NASDAQ ARCT opened at $16.07 on Wednesday. Arcturus Therapeutics Holdings Inc. has a 52 week low of $14.30 and a 52 week high of $45.00. The firm has a market capitalization of $435.34 million, a P/E ratio of -7.24 and a beta of 2.62. The company has a 50-day moving average price of $17.12 and a 200-day moving average price of $19.12.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.